Skip to main content
SpringerLink
Log in

Efficacy of Neoadjuvant Intratumoral Darleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM)

  • ASO Research Letter
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma European consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer. 1990;63:201–17.

    Article  Google Scholar 

  2. Marabelle A, Tselikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Annal Oncol: Off J Eur Soc Med Oncol. 2017;28(12):33–43.

    Article  Google Scholar 

  3. Bommareddy PK, Silk AW, Kaufman HL. Intratumoral approaches for the treatment of melanoma. Cancer J. 2017;23(1):40–7.

    Article  Google Scholar 

  4. Miura JT, Zager JS. Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma. Future Oncol. 2019;15(32):3665–74.

    Article  CAS  Google Scholar 

  5. Zawit M, Swami U, Awada H, Arnouk J, Milhem M, Zakharia Y. Current status of intralesional agents in treatment of malignant melanoma. Annal Transl Med. 2021;9(12):1038.

    Article  CAS  Google Scholar 

  6. Danielli R, Patuzzo R, Di Giacomo AM, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IV M1a melanoma patients: results of a phase II study. Cancer Immunol, Immunother: CII. 2015;64(8):999–1009.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Areeba Saif MD, Alexander J. Rossi MD & Jonathan M. Hernandez MD

  2. Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    Amod Sarnaik MD & Jonathan S. Zager MD

Authors
  1. Areeba Saif MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander J. Rossi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amod Sarnaik MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonathan M. Hernandez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jonathan S. Zager MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jonathan M. Hernandez MD or Jonathan S. Zager MD.

Ethics declarations

Disclosure

JSZ—Consultant to Philogen, research funding from Philogen. Dr. Sarnaik is a co-inventor on a patent application with Provectus Biopharmaceuticals. Moffitt Cancer Center has licensed intellectual property (IP) related to the proliferation and expansion of tumor infiltrating lymphocytes (TILs) to Iovance Biotherapeutics. Dr. Sarnaik is a co-inventor on such intellectual property. Dr. Sarnaik has received ad hoc consulting fees from Iovance Biotherapeutics, Guidepoint, Defined Health, Huron Consulting Group, KeyQuest Health Inc., Istari, and Gerson Lehrman Group; he has also received speaker fees from Physicians’ Educational Resource (PER) LLC, Medscape, and Medstar Health.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 175 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saif, A., Rossi, A.J., Sarnaik, A. et al. Efficacy of Neoadjuvant Intratumoral Darleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM). Ann Surg Oncol 29, 3377–3378 (2022). https://doi.org/10.1245/s10434-022-11447-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-11447-x

Search

Navigation